Excellent discussion by Charmaine Lok on PISCES trial (on her birthday), evolved from the earlier FISH study. Despite positive findings of fish oil in cv outcomes, vascular access patency, FISH was viewed as a “negative”. @CSNSCN

Great connecting with an inspiring group of community nephrologists at CSNAGM 2026. Grateful for the shared learning, collaboration, and dedication toward improving kidney care across Canada. #CSN2026 @CSNSCN

Important session by @ShaifaliSandal on disaster and emergency preparedness in kidney care. With increasing natural, human-caused, and infrastructure-related disasters globally, CKD patients face higher hospitalization risks & general population faces increased AKI risk. @CSNSCN

Lisa Miller and Danielle Moorman reviewed CKM mineral bone disease management. Vitamin D, phosphate restriction, and phosphate binders showed limited outcome benefits and may negatively impact quality of life. Strong emphasis on individualized management @CSNSCN

Excellent discussions on Conservative Kidney Management (CKM) by Sara Davison. A key message: CKM should be individualized, with goals centered around quality of life than strict biochemical normalization. Practice patterns vary significantly across Canada. #CSN2026 @CSNSCN

The Canadian Society of Nephrology Annual General Meeting 2026 welcome session has officially started! Looking forward to an exciting few days ahead at #CSN2026 #Nephrology @CSNSCN

Excellent session on the evolving understanding of nephrotic syndrome as an autoimmune disease. Podocyte injury remains central, with nephrin now recognized not just as a structural protein, but also a key signalling molecule maintaining podocyte integrity. #CSN2026 @CSNSCN

Fascinating session on the potential role of Virtual Reality (VR) in hemodialysis care. With >30,000 Canadians dependent on HD, mental and somatic symptom burden remains substantial. VR may offer an innovative supportive strategy. #CSN2026 @CSNSCN

A key goal is embedding automated risk alerting into the provincial Epic system to help close these gaps. Exciting to hear about the upcoming UPRISING CKD trial, which will use personalized risk prediction to improve implementation of nephrology guidelines in CKD care. @CSNSCN

“Prediction to Practice” session by Tyrone Harrison discussing how kidney risk prediction models can move beyond theory into real-world clinical frameworks. #CSN2026 @CSNSCN

Louise Moist reviewed key evidence from the DRIVE, PIVOTAL, and FIND-CKD trials, emphasizing the cardiovascular and ESA-sparing benefits of proactive iron therapy, while carefully balancing the risks and benefits of IV versus oral iron supplementation in CKD care. @CSNSCN

Insightful session by Wendy Lim on iron deficiency anemia in CKD. Increased hepcidin contributes to functional iron deficiency & reduced erythropoiesis, with anemia prevalence approaching 53% in CKD stage 5. #CSN2026 @CSNSCN

Excellent talk by Dorry Segev on AI in healthcare. Artificial neural networks help train AI through pattern recognition — AI is not “thinking” independently. Generative AI/LLMs fundamentally work by predicting the next word or thought based on learned patterns. @CSNSCN #CSN2026

Prior abdominal surgery alone may not significantly affect outcomes unless adhesions are present. Lower eGFR at initiation appears associated with higher catheter-related complications and “rocky starts.” #CSN2026 @CSNSCN

Excellent session by Matt Oliver on optimizing peritoneal dialysis (PD) utilization. A key message: focus on true eligibility and avoid empirical contraindications that may unnecessarily limit PD uptake. #CSN2026 @CSNSCN

In the current era of available therapies, no patient with diabetic kidney disease should routinely progress to dialysis without optimized evidence-based treatment. A practical 4-step remission-focused approach to CKD care may change long-term outcomes. @CSNSCN

Vlado Perkovic - highlighting the evolving rx landscape aimed IgAN remission. Sibeprenlimab (APRIL inhibitor) & Atacicept (APRIL/BAFF inhibitor) - shown proteinuria reduction/remission results. Barrier is clinical inertia in timely diagnosis and rx escalation. @CSNSCN

Lunch symposium by Navdeep Tangri: powerful message: albuminuria is the gatekeeper of CKD progression, but CKD progression is no longer inevitable. With the right therapies, at the right time, in the right combinations, remission is increasingly achievable. #CSN2026 @CSNSCN